Copyright: ©Author(s) 2026.
World J Gastroenterol. Apr 14, 2026; 32(14): 116529
Published online Apr 14, 2026. doi: 10.3748/wjg.v32.i14.116529
Published online Apr 14, 2026. doi: 10.3748/wjg.v32.i14.116529
Table 4 Adverse events, n (%)
| Event | Thalidomide treatment (n = 62) | ||
| Grade 1 | Grade 2 | Total | |
| Any adverse event | 17 (27.4) | 7 (11.3) | 23 (37.1) |
| Nausea | 3 (4.8) | 0 | 3 (4.8) |
| Constipation | 0 | 5 (6.5) | 4 (6.5) |
| Dizziness | 9 (14.5) | 0 | 9 (14.5) |
| Somnolence | 8 (12.9) | 0 | 8 (12.9) |
| Blurred vision | 1 (1.6) | 0 | 1 (1.6) |
| Rash | 3 (4.8) | 0 | 3 (4.8) |
| Limb numbness | 0 | 1 (1.6) | 1 (1.6) |
| Peripheral edema | 1 (1.6) | 0 | 1 (1.6) |
| DVT of lower extremity | 0 | 1 (1.6) | 1 (1.6) |
- Citation: Huang XY, Zhong QH, Kuang YY, Li ZJ, Huang BJ, He YJ, Zhu MM, Guan Q, Li XY, Qin QY, Ma TH. Thalidomide for refractory hemorrhagic chronic radiation proctitis secondary to pelvic malignancy radiotherapy: A phase II clinical trial. World J Gastroenterol 2026; 32(14): 116529
- URL: https://www.wjgnet.com/1007-9327/full/v32/i14/116529.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i14.116529